Securities code: 600781 securities abbreviation: St Furen Announcement No.: 2022-008 Furen Group Pharmaceutical Co.Ltd(600781)
Notice on relevant risks
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear individual and joint liabilities for the authenticity, accuracy and completeness of its contents.
The board of directors of Furen Group Pharmaceutical Co.Ltd(600781) (hereinafter referred to as “the company”) hereby reminds all investors of the relevant risks of the company as follows. Please pay attention to the investment risks.
1、 Relevant risk tips
1. At present, the company has the risk of sustainable operation ability
According to the relevant contents of the semi annual report of 2021 and the report of the third quarter of 2021, the overdue debt of the company was 3.068 billion yuan by the end of the third quarter of 2021; In the first half of 2021, the company achieved an operating revenue of 902 million yuan, a year-on-year decrease of 32.65%. In the third quarter of 2021, the company achieved an operating revenue of 378 million yuan, a year-on-year decrease of 45.45%; In the half year of 2021, the net profit attributable to shareholders of listed companies was -294 million yuan, the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was -296 million yuan, the net profit attributable to shareholders of Listed Companies in the third quarter of 2021 was -238 million yuan, and the net profit attributable to shareholders of listed companies after deducting non recurring profits and losses was -209 million yuan, with a large amount of loss. In addition, the company’s capital liquidity is difficult, facing the financial pressure of overdue debts and joint and several compensation for external guarantees. At the same time, it involves many lawsuits and the freezing of some bank accounts and assets.
2. Risk of fund occupation and illegal guarantee
As of the disclosure date of this announcement, the balance of loans provided by the company to the controlling shareholder Furen Pharmaceutical Group Co., Ltd. and related parties was 1687.7281 million yuan, the company provided joint and several liability guarantee to the controlling shareholder and related parties was 2479.6531 million yuan, and the balance of guarantee was 1746.9517 million yuan. The above matters without the approval of the company’s authorized decision-making body constitute the occupation of funds and illegal guarantee of related parties, which is expected to be unresolved within one month.
2、 Controlling shareholder’s equity freeze risk
Up to now, Furen group holds 673,58881 shares of the company (including 38539326 shares of restricted circulation shares and 28819555 shares of unlimited circulation shares), accounting for 10.74% of the total share capital of the company. All these shares have been sealed up and frozen by the judiciary, and there are many waiting for freezing.
3、 Other matters
The board of directors of the company confirms that, except for the disclosed matters, the company has no matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange or the planning and intention related to such matters, and the board of directors of the company has not been informed of the matters that should be disclosed but not disclosed in accordance with the relevant provisions of the Listing Rules of Shanghai Stock Exchange Information that may have a great impact on the stock trading price of the company. After further verification of relevant matters, the company will disclose them in accordance with relevant rules.
The information disclosure newspaper designated by the company is Shanghai Securities News, and the information disclosure website is www.sse.com of Shanghai Stock Exchange com. cn.， The information released by the company is subject to the announcement information published in the above designated newspapers and websites. The company will timely disclose the information in strict accordance with the provisions and requirements of relevant laws and regulations. Please pay attention to the investment risks.
It is hereby announced.
Furen Group Pharmaceutical Co.Ltd(600781) board of directors February 7, 2022
